FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratorios. FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics Contract Development and Manufacturing Organization (CDMO) has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development laboratories. As a part of a capital investment of approximately 13 billion yen (approx. $120 million USD) in the gene therapy field by FUJIFILM Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacent to FDB’s existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas and forms part of the company’s strategy to meet the growing demands in the Viral Gene Therapy Market. The gene therapy market forecast for CDMOs is expected to grow to $1.7Bn by 2025.
FUJIFILM Diosynth Biotechnologies Announces $55 Million USD Investment To Expand Gene Therapy Development Capabilities
by admin | Nov 18, 2019 | Funding, Partnerships